Search results for "NONALCOHOLIC FATTY LIVER DISEASE"

showing 10 items of 139 documents

Emerging Increase in the prevalence and severity of nonalcoholic fatty liver disease: epidemiological study from general Mediterranean population

2016

Background and Aims: The worldwide spread of obesity and diabetes is leading to a drastic increase in nonalcoholic fatty liver disease (NAFLD) and its complications.We aimed to assess prevalence of NAFLD and of its severity among a general Mediterranean population. Methods:We considered 886 consecutive individuals included in the ABCD study (ISRCTN15840340). Hepatic ultrasound (US) was used to diagnose steatosis and FibroScan (M and XL probe) to measure liver stiffness and controlled attenuation parameter (CAP). Liver stiffness >6.9 KPa was considered suggestive of significant liver fibrosis (Petta S et al., Hepatology 2015), and CAP ≥ 310 dB was considered suggestive of moderate-severe …

Mediterranean climateeducation.field_of_studymedicine.medical_specialtyHepatologybusiness.industryPopulationGastroenterologymedicine.diseaseGastroenterologyobesity ABCD fatty liver disease hepatosteatosisInternal medicineNonalcoholic fatty liver diseaseEpidemiologyMedicineeducationbusiness

researchProduct

Noninvasive evaluation of hepatic steatosis and fibrosis in OSA patients at diagnosis

2012

NONALCOHOLIC FATTY LIVER DISEASE SLEEP APNEASettore MED/10 - Malattie Dell'Apparato Respiratorio

researchProduct

Need for liver evaluation in polycystic ovary syndrome

2007

Medicine is changing and requires a more in-depth knowledge also in fields that were previously considered completely different and dedicated to other specialists. A good example of this general trend is the paper by Cerda et al. [1] that shows a high prevalence of nonalcoholic fatty liver disease (NAFLD) in women with Polycystic Ovary Syndrome (PCOS). The authors studied 41 young women with PCOS and found that 17 patients (41%) had NAFLD. In addition, 7 patients with NAFLD had increased aminotransferase levels raising the possibility of a transition to nonalcoholic steatohepatitis (NASH). Other reports have shown similar data recently [2–5]. It is time therefore that doctors caring for pat…

Nonalcoholic steatohepatitisMetabolic Syndromemedicine.medical_specialtySettore MED/12 - GastroenterologiaSettore MED/09 - Medicina InternaHepatologyPCOS Liver function NASH NAFLDbusiness.industrynutritional and metabolic diseasesmedicine.diseaseGastroenterologyPolycystic ovarySettore MED/13 - EndocrinologiaFatty LiverLiver Function TestsInternal medicineNonalcoholic fatty liver diseasePrevalenceMedicineHumansFemalebusinessPolycystic Ovary Syndrome

researchProduct

Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected?

2020

Pharmacologymedicine.medical_specialtyClinical Trials as Topicbusiness.industryNAFLD - Nonalcoholic Fatty Liver DiseaseGeneral MedicineClinical trialPharmacotherapyNon-alcoholic Fatty Liver DiseaseResearch DesignInternal medicineLifestyle interventionmedicineHumansPharmacology (medical)businessLife StyleExpert opinion on investigational drugs

researchProduct

Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes.

2020

Background: Naturally occurring variation in Membrane-bound O-acyltransferase domain-containing 7 (MBOAT7), encoding for an enzyme involved in phosphatidylinositol acyl-chain remodelling, has been associated with fatty liver and hepatic disorders. Here, we examined the relationship between hepatic Mboat7 down-regulation and fat accumulation. Methods: Hepatic MBOAT7 expression was surveyed in 119 obese individuals and in experimental models. MBOAT7 was acutely silenced by antisense oligonucleotides in C57Bl/6 mice, and by CRISPR/Cas9 in HepG2 hepatocytes. Findings: In obese individuals, hepatic MBOAT7 mRNA decreased from normal liver to steatohepatitis, independently of diabetes, inflammatio…

Research paperTGFβ Transforming Growth Factor BetaIntracellular SpaceCRISPR Clustered Regularly Interspaced Short Palindromic RepeatshHEPS Human HepatocytesMice0302 clinical medicineLPIAT1DAG Diacylglyceroli.p. Intraperitonealmedia_commonFatty AcidsGeneral Medicine3. Good health030220 oncology & carcinogenesisHOMA-IR homeostasis Model Assessment of Insulin ResistanceMPO morpholinolcsh:Medicine (General)medicine.medical_specialtyPE Phosphatidyl-EthanolamineNashGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesTNFα tumor Necrosis Factor AlphaLDL Low Density LipoproteinsHyperinsulinismNAFLDSD Standard Dietmedia_common.cataloged_instanceHumansCPT1 Carnitine Palmitoyltransferase IPhosphatidylinositolGene SilencingEuropean unionVLDL Very Low Density Lipoproteinlcsh:RhHSC Human Hepatic Stellate Cellsmedicine.diseaseLipid MetabolismOA Oleic AcidCI Confidence IntervalMboat7 Membrane bound O-acyltransferase domain containing 7MCD methionine choline deficient diet030104 developmental biologyEndocrinologychemistryCDP Cytidine-DiphosphateFOXO1 Forkhead Box protein O1NAFLD nonalcoholic fatty liver diseaseSteatohepatitisBMI Body Mass IndexCL CardiolipinAcyltransferases0301 basic medicineAlcoholic liver diseaseCXCL10 C-X-C Motif Chemokine 10lcsh:Medicinechemistry.chemical_compoundNon-alcoholic Fatty Liver DiseaseIFG Impaired Fasting GlucoseAPOB Apolipoprotein BNonalcoholic fatty liver diseasePIP Phosphatidyl-Inositol-PhosphateSteatohepatitisqRT-PCR quantitative Real Time Polymerase Chain ReactionMice Knockoutlcsh:R5-920ORO Oil Red O StainingPI PhosphatidylinositolFatty liverTM6SF2 Transmembrane 6 Superfamily Member 2PhospholipidTAG TriglyceridesNASH Nonalcoholic SteatohepatitisLipogenesisLPA Lyso-Phosphatidic AcidPhosphatidylinositolSignal TransductionPS Phosphatidyl-SerinePA Palmitic AcidALD alcoholic liver diseasePC Phosphatidylcholinei.v. IntravenousFATP1 Fatty Acid Transport Protein 1Models BiologicalInternal medicinemedicineAnimalsNonalcoholic fatty liver diseasePPARα Peroxisome Proliferator-Activated Receptor alphaObesityG3P Glyceraldehyde-3-PhosphateSREBP1c Sterol Regulatory Element-Binding Protein 1HDL High Density Lipoproteinsbusiness.industryPI3K Phosphatidylinositol 3 KinaseMembrane ProteinsNHEJ Non-Homologues End JoiningPNPLA3 Patatin-like Phospholipase Domain-containing-3MTTP Microsomal Triglyceride Transfer ProteinLPIAT1 Lysophosphatidylinositol Acyltransferase 1TMC4 Transmembrane Channel-Like 4Disease Models AnimalGene Expression RegulationHepatocytesFOXA2 Forkhead Box A2mTOR mammalian target of RapamycinSteatosisInsulin ResistancebusinessPG Phosphatidyl-GlycerolFABP1 Fatty Acid-Binding Protein 1 FAS Fatty Acid SynthaseT2DM Type 2 Diabetes MellitusEBioMedicine

researchProduct

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

2021

Introduction: In the REFLECT trial, lenvatinib was found to be noninferior compared to sorafenib in terms of overall survival. Here, we analyze the effects of lenvatinib in the real-life experience of several centers across the world and identify clinical factors that could be significantly associated with survival outcomes. Methods: The study population was derived from retrospectively collected data of HCC patients treated with lenvatinib. The overall cohort included western and eastern populations from 23 center in five countries. Results: We included 1,325 patients with HCC …

Second lineSettore MED/12 - GastroenterologiaOncologyHepatologyHepatocellular carcinomaLenvatinibNonalcoholic fatty liver diseaseTyrosine kinase inhibitors.ALBINonalcoholic steatohepatitiNeutrophils to lymphocyte ratioOutcome

researchProduct

The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease

2015

In nonalcoholic fatty liver disease, the influence of severity of steatosis on liver stiffness measurement (LSM) is poorly studied and still debated. We assessed the impact of steatosis severity and its ultrasonographic (US) sign, severe bright liver echo pattern, on LSM values and on transient elastography accuracy for the diagnosis of liver fibrosis in a cohort of consecutive patients with nonalcoholic fatty liver disease. Patients (n = 253) were assessed by clinical, US, and histological (Kleiner score) features. Transient elastography was performed using the M probe. Among patients with low amounts of fibrosis (F0-F1 and F0-F2), median LSM values, expressed in kilopascals, were signific…

Settore MED/12 - Gastroenterologiamedicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industrySettore MED/08 - Anatomia PatologicaHepatologymedicine.diseaseGastroenterologyFibrosisInternal medicineLiver biopsySeverity of illnessCohortNonalcoholic fatty liver diseasemedicineLSM FIBROSIS NAFLDSteatosisbusinessTransient elastographyHepatology

researchProduct

Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation

2012

The metabolic syndrome (MetS) might contribute to morbidity after orthotopic liver transplantation (OLT). For this reason, we searched for MetS-associated risk factors and analyzed the link with nonalcoholic fatty liver disease (NAFLD) in OLT recipients. De novo MetS affected 32.9% of our cohort (n = 170) within 2 years after OLT. Multivariate analysis identified glycosylated hemoglobin (HbA1c) levels ≥5% [odds ratio (OR) = 3.5; 95% confidence interval (CI) = 1.56-8.13, P = 0.003], diabetes mellitus (OR = 4.31, CI = 1.69-10.99, P = 0.002), and arterial hypertension (OR = 4.59, CI = 1.46-14.49, P = 0.009) as independent risk factors for de novo MetS. MetS incidence correlated with steroid do…

Transplantationmedicine.medical_specialtybusiness.industryFatty liverOdds ratiomedicine.diseaseGastroenterologysurgical procedures operativeEndocrinologyDiabetes mellitusInternal medicineNonalcoholic fatty liver diseasemedicineRisk factorMetabolic syndromebusinessBody mass indexDyslipidemiaTransplant International

researchProduct

Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.

2018

Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population with a range of 13.5% in Africa and 31.8% in the Middle East. Nonalcoholic fatty liver disease is closely associated with a constellation of metabolic comorbidities which include: obesity, type 2 diabetes mellitus, hypertension, and hypercholesteremia. In fact, the increasing number of metabolic comorbidities not only increases the prevalence of NAFLD but also places patients at higher risk for progressive liver disease. As such, NAFLD is presently among the top etiologies for hepatocellular carcinoma and an indication for liver transplantation (LT) in the United States. Therefore, the following recommendati…

United StateLiver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularTissue and Organ ProcurementWaiting ListsLiver Cirrhosimedicine.medical_treatmentComorbidity030230 surgeryLiver transplantationdigestive system03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineEpidemiologyNonalcoholic fatty liver diseasePrevalenceMedicineHumansMetabolic SyndromeTransplantationbusiness.industryRisk FactorIncidencePatient SelectionLiver Neoplasmsnutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseaseComorbidityObesitydigestive system diseasesUnited StatesLiver TransplantationLiver NeoplasmWaiting ListDisease Progression030211 gastroenterology & hepatologyMetabolic syndromebusinessHumanTransplantation

researchProduct

Microbiome and Diseases: Hepatic Disorders

2018

Intensive research efforts aim to understand the multifaceted molecular mechanisms underlying disease onset and progression of nonalcoholic fatty liver disease (NAFLD) and alcohol-induced liver disease (ALD). Taken together, NAFLD and ALD are the most common liver diseases worldwide, and universally accepted therapies other than lifestyle interventions either focusing on weight reduction and physical exercise or alcohol abstinence are lacking. During the last decade, alterations of intestinal microbiota composition and intestinal barrier function leading to an increased translocation of bacterial endotoxin and of metabolites originating from an altered intestinal microbiome are emerging as …

business.industryPhysical exercisemedicine.diseaseBioinformaticsLiver diseaseWeight lossNonalcoholic fatty liver diseasemedicineMicrobiomemedicine.symptombusinessHepatic disordersBarrier functionAlcohol Abstinence

researchProduct